Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC
laurabbook@gmail.com2021-03-22T12:16:54-07:00*February 2021* In EGFR-mutant non–small cell lung cancer (NSCLC) and brain metastases, oral osimertinib (Tagrisso) achieved rapid, high, and uniform